DrugPatentWatch Database Preview
Eagle Pharms Company Profile
What is the competitive landscape for EAGLE PHARMS, and when can generic versions of EAGLE PHARMS drugs launch?
EAGLE PHARMS has five approved drugs.
There are twenty-four US patents protecting EAGLE PHARMS drugs. There is one tentative approval on EAGLE PHARMS drugs.
Summary for Eagle Pharms
| US Patents: | 24 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 5 |
Drugs and US Patents for Eagle Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eagle Pharms | ARGATROBAN IN SODIUM CHLORIDE | argatroban | INJECTABLE;INTRAVENOUS | 022434-001 | Jun 29, 2011 | RX | Yes | Yes | 7,589,106 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eagle Pharms | RYANODEX | dantrolene sodium | FOR SUSPENSION;INTRAVENOUS | 205579-001 | Jul 22, 2014 | RX | Yes | Yes | 7,758,890 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eagle Pharms | BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 205580-001 | May 15, 2018 | RX | Yes | Yes | 9,572,796 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eagle Pharms | RYANODEX | dantrolene sodium | FOR SUSPENSION;INTRAVENOUS | 205579-001 | Jul 22, 2014 | RX | Yes | Yes | 9,884,044 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eagle Pharms | BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 205580-001 | May 15, 2018 | RX | Yes | Yes | 9,265,831 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eagle Pharms | BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 205580-001 | May 15, 2018 | RX | Yes | Yes | 10,010,533 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | 9,265,831 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for EAGLE PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 100 mg/4 mL (25 mg/mL) multiple-dose vials | ➤ Subscribe | 2017-05-04 |
International Patents for Eagle Pharms Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Canada | 2867343 | ➤ Sign Up |
| Japan | 2015510940 | ➤ Sign Up |
| Japan | 5795600 | ➤ Sign Up |
| Ukraine | 94036 | ➤ Sign Up |
| Australia | 2013327563 | ➤ Sign Up |
| Japan | 2008526991 | ➤ Sign Up |
| Denmark | 2528602 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Eagle Pharms Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| /2013 | Austria | ➤ Sign Up | PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317 |
| 172 | Luxembourg | ➤ Sign Up | PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL) |
| 60002 | Netherlands | ➤ Sign Up | PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
